lomefloxacin has been researched along with cefotaxime in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Berger, NS; Crawford, ED; Davis, MA; Donohue, RE | 1 |
Childs, SJ; Klimberg, IW; Klimberg, SR; Madore, RJ | 1 |
Weinstein, MP | 1 |
Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
1 review(s) available for lomefloxacin and cefotaxime
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for lomefloxacin and cefotaxime
Article | Year |
---|---|
Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Bacteremia; Cefotaxime; Female; Female Urogenital Diseases; Fluoroquinolones; Humans; Injections; Male; Male Urogenital Diseases; Postoperative Complications; Premedication; Quinolones; Urethra; Urinary Tract Infections | 1992 |
A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Cefotaxime; Female; Fluoroquinolones; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Middle Aged; Premedication; Quinolones; Urethra; Urinary Tract Infections; Urogenital System | 1992 |
4 other study(ies) available for lomefloxacin and cefotaxime
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Comparative in vitro activity of lomefloxacin and other antimicrobials against 597 microorganisms causing bacteremia.
Topics: Anti-Bacterial Agents; Bacteria; Cefotaxime; Ceftazidime; Enoxacin; Fluoroquinolones; Humans; Imipenem; Microbial Sensitivity Tests; Norfloxacin; Quinolones; Sepsis; Tobramycin | 1988 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |